{"id":16946,"date":"2022-04-28T16:08:07","date_gmt":"2022-04-28T20:08:07","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=16946"},"modified":"2022-05-05T14:02:50","modified_gmt":"2022-05-05T18:02:50","slug":"webinar-recap-key-findings-from-ees-final-10-survey","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/tr\/webinar-recap-key-findings-from-ees-final-10-survey\/","title":{"rendered":"Web Semineri \u00d6zeti: EE'nin \"Final 10%\" Anketinden \u00d6nemli Bulgular"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Emily's Entourage (EE), 6 Nisan 2022 tarihinde Emily's Entourage'\u0131n bulgular\u0131n\u0131 payla\u015fmak \u00fczere bir bilgilendirme webinar\u0131 d\u00fczenledi. <\/span><a href=\"https:\/\/www.emilysentourage.org\/tr\/ee-publishes-first-ever-final-10-survey-and-announces-informational-webinar\/\"><span style=\"font-weight: 400;\">a\u00e7ili\u015f k\u00fcresel anketi\u0307<\/span><\/a><span style=\"font-weight: 400;\"> mevcut mutasyon hedefli tedavilerden yararlanamayan kistik fibrozisli (KF) ki\u015filerin sa\u011fl\u0131\u011f\u0131 ve perspektifleri \u00fczerine. Sonu\u00e7lar \u015fu dergide yay\u0131mlanm\u0131\u015ft\u0131r <\/span><em><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35170259\/\"><span style=\"font-weight: 400;\">Pediatrik Pulmonoloji.<\/span><\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Ara\u015ft\u0131rma makalesinin ortak yazar\u0131 ve EE Bilimsel Dan\u0131\u015fma Kurulu \u00fcyesi Dr. Jennifer L. Taylor-Cousar, MD, MSCS, ATSF, \u00f6nemli anket bulgular\u0131n\u0131 sundu ve KF'li ki\u015filer ve sevdikleri, ara\u015ft\u0131rmac\u0131lar, klinisyenler ve biyoteknoloji ve ila\u00e7 end\u00fcstrilerinin \u00fcyelerini i\u00e7eren kat\u0131l\u0131mc\u0131lar i\u00e7in \u00e7\u0131kar\u0131mlar\u0131n alt\u0131n\u0131 \u00e7izdi.<\/span><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.youtube.com\/watch?v=Wj50OrnfIzs\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone wp-image-16948\" src=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-300x166.png\" alt=\"\" width=\"1385\" height=\"765\" srcset=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-300x166.png 300w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-1024x565.png 1024w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-768x424.png 768w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-1536x848.png 1536w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-18x10.png 18w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar-600x331.png 600w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar.png 1708w\" sizes=\"(max-width: 1385px) 100vw, 1385px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Bulgular\u0131n g\u00f6zden ge\u00e7irilmesinde \u00fc\u00e7 ana tema ortaya \u00e7\u0131km\u0131\u015ft\u0131r: KF'nin hem hastal\u0131\u011f\u0131 olan ki\u015filerin hem de bak\u0131c\u0131lar\u0131n\u0131n ruh sa\u011fl\u0131\u011f\u0131 \u00fczerindeki etkisi; KF'li az\u0131nl\u0131klar i\u00e7in mevcut olan e\u015fitsizlikler ve klinik ara\u015ft\u0131rmaya kat\u0131l\u0131m ve i\u015fe al\u0131mla ilgili zorluklar.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">KF'den en \u00e7ok etkilenen ya\u015fam unsurlar\u0131 soruldu\u011funda, kat\u0131l\u0131mc\u0131lar\u0131n 45,5%'si \"ruh sa\u011fl\u0131\u011f\u0131\" ve 45,2%'si \"gelecek planlar\u0131\" yan\u0131t\u0131n\u0131 vermi\u015ftir.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Kat\u0131l\u0131mc\u0131lar ayr\u0131ca kendilerini \"geride b\u0131rak\u0131lm\u0131\u015f\" hissettiklerini - ruh sa\u011fl\u0131klar\u0131n\u0131n sadece KF'li olmalar\u0131ndan de\u011fil, KF'li insanlar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011funun eri\u015febildi\u011fi tedaviye uygun olmamalar\u0131ndan da etkilendi\u011fini bildirmi\u015flerdir. Dr. Taylor-Cousar, mutasyon hedefli tedavilerden faydalanamayan KF'li ki\u015filerin son 10%'sinin k\u0131smen bu d\u0131\u015flanman\u0131n bir sonucu olarak t\u0131bbi travma ya\u015fad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klam\u0131\u015ft\u0131r.<\/span><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.youtube.com\/watch?v=Wj50OrnfIzs\"><img decoding=\"async\" class=\"alignnone wp-image-16949\" src=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-300x169.png\" alt=\"\" width=\"1385\" height=\"780\" srcset=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-300x169.png 300w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-1024x577.png 1024w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-768x432.png 768w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-18x10.png 18w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar-600x338.png 600w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/webinar.png 1291w\" sizes=\"(max-width: 1385px) 100vw, 1385px\" \/><\/a><\/p>\n<blockquote><p><span style=\"font-weight: 400;\">\"A\u00e7\u0131k ve net bir \u015fekilde ortaya \u00e7\u0131kan \u015fey, geride kalmaya dair inan\u0131lmaz bir korku oldu\u011fudur. \u0130nsanlar, toplulu\u011fun 90% ile yetinip yoluna devam edece\u011finden ve son birka\u00e7 y\u0131l veya on y\u0131lda g\u00f6rd\u00fc\u011f\u00fcm\u00fcz KF tedavileri geli\u015ftirmeye y\u00f6nelik ola\u011fan\u00fcst\u00fc ba\u011fl\u0131l\u0131k ve odaklanman\u0131n azalaca\u011f\u0131ndan korkuyor. Bunu duymak \u00e7ok derindi.\" - Emily Kramer-Golinkoff, kurucu ortak, Emily's Entourage<\/span><\/p><\/blockquote>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Dr. Taylor-Cousar ayr\u0131ca tarihsel olarak marjinalize edilmi\u015f gruplar\u0131n mutasyonlar\u0131 nedeniyle mod\u00fclat\u00f6rlere hak kazanma olas\u0131l\u0131klar\u0131n\u0131n daha d\u00fc\u015f\u00fck oldu\u011funun alt\u0131n\u0131 \u00e7izmi\u015ftir. \u00d6rne\u011fin, KF'li beyazlar\u0131n yakla\u015f\u0131k 90%'si mutasyon hedefli tedavilere hak kazan\u0131rken, siyahlar\u0131n sadece 70%'si ve Hispaniklerin 76%'si hak kazanmaktad\u0131r.\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Klinik ara\u015ft\u0131rma i\u015fe al\u0131mlar\u0131nda e\u015fitli\u011fe \u00f6ncelik verilmesi konusunda Dr. Taylor-Cousar, toplumumuzda kurumsalla\u015fm\u0131\u015f olan k\u00fclt\u00fcrel \u00f6nyarg\u0131lar\u0131 g\u00f6z \u00f6n\u00fcnde bulundurarak KF'li t\u00fcm insanlara eri\u015fim sa\u011flaman\u0131n \u00f6nemini payla\u015ft\u0131.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Dr. Taylor-Cousar'\u0131n sunumunu k\u0131sa bir soru-cevap b\u00f6l\u00fcm\u00fc takip etti. Webinar\u0131n tamam\u0131n\u0131 a\u015fa\u011f\u0131da g\u00f6r\u00fcnt\u00fcleyebilirsiniz.<\/span><\/p>\n<p><iframe title=\"Webinar: 2021 &quot;Final 10%&quot; Anket Bulgular\u0131 ve Soru-Cevap\" width=\"960\" height=\"540\" src=\"https:\/\/www.youtube.com\/embed\/Wj50OrnfIzs?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Taylor-Cousar, webinar soru-cevap b\u00f6l\u00fcm\u00fcn\u00fcn ard\u0131ndan ek sorular\u0131 da yan\u0131tlad\u0131.<\/span><\/p>\n<h5><b>S: Yakla\u015fan tedaviler i\u00e7in zaman \u00e7izelgesi nedir?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h5>\n<p><span style=\"font-weight: 400;\">A (Dr. Taylor-Cousar): Nonsense mutasyonlar\u0131 olan uygun kat\u0131l\u0131mc\u0131lar i\u00e7in ELX-02 art\u0131 ivacaftor (Kalydeco\u00ae) kullan\u0131m\u0131n\u0131 inceleyen bir deneme \u015fu anda kay\u0131t almaktad\u0131r (*NCT04135495). D\u00fczeltilmi\u015f CFTR genini akci\u011ferlere iletecek bir adeno-ili\u015fkili vir\u00fcs gen terapisi olan 4D-710'un bir denemesi yak\u0131n zamanda kay\u0131t almaya ba\u015flad\u0131 (*NCT05248230). CFTR'ye y\u00f6nelik tedavilerin ek erken faz denemelerinin 2022'nin ikinci yar\u0131s\u0131nda ba\u015flamas\u0131n\u0131 bekliyoruz.\u00a0<\/span><\/p>\n<h5><b>S: Akci\u011fer ve\/veya karaci\u011fer nakli olduysam bir ara\u015ft\u0131rmaya kat\u0131lmaya uygun muyum?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h5>\n<p><span style=\"font-weight: 400;\">C: Ne yaz\u0131k ki, karaci\u011fer veya akci\u011fer nakli ge\u00e7irmi\u015f olan KF'li ki\u015filer b\u00fcy\u00fck olas\u0131l\u0131kla yeni KF tedavilerinin klinik \u00e7al\u0131\u015fmalar\u0131n\u0131n \u00e7o\u011funa kat\u0131lamayacaklard\u0131r. Yeni tedaviler onayland\u0131\u011f\u0131nda, nakil ge\u00e7irmi\u015f bireyler yeni tedavileri kullanma se\u00e7eneklerini nakil ekipleriyle g\u00f6r\u00fc\u015fmelidir.\u00a0\u00a0\u00a0<\/span><\/p>\n<h5><b>S: Nadir ve anlams\u0131z CFTR mutasyonlar\u0131na sahip ki\u015filer i\u00e7in yeni \"yukar\u0131 ak\u0131\u015f\" tedavilerinin \u00f6tesinde, en \u00e7ok hangi \"a\u015fa\u011f\u0131 ak\u0131\u015f\" yakla\u015f\u0131mlar\u0131na ihtiya\u00e7 duyuluyor?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h5>\n<p><span style=\"font-weight: 400;\">C: CFTR mod\u00fclat\u00f6rlerine uygun olmayan veya bunlar\u0131 tolere edemeyen ki\u015filer, mukosiliyer klirensi art\u0131racak ve enfeksiyon ve inflamasyonu kontrol alt\u0131na alacak tedavilere ihtiya\u00e7 duymaya devam etmektedir. Enfeksiyonu tedavi etmek i\u00e7in yeni yakla\u015f\u0131mlar ve g\u00fcvenli ve etkili anti-enflamatuar tedavilerin geli\u015ftirilmesi \u00f6zellikle \u00f6nemlidir.\u00a0<\/span><\/p>\n<h5><b>S: KF'nin nadir mutasyonlar\u0131, az\u0131nl\u0131k topluluklar\u0131nda yetersiz tarama ve testler nedeniyle yetersiz te\u015fhisin bir fonksiyonu olabilir mi? (Belki de o kadar nadir de\u011fillerdir?)<\/b><\/h5>\n<p><span style=\"font-weight: 400;\">C: KF'nin tarihsel olarak yaln\u0131zca Avrupa k\u00f6kenli ki\u015filerde g\u00f6r\u00fcld\u00fc\u011f\u00fc d\u00fc\u015f\u00fcn\u00fcld\u00fc\u011f\u00fcnden, Siyah, Yerli ve beyaz olmayan ki\u015filer olarak kategorize edilen ki\u015filerde daha yayg\u0131n olarak g\u00f6r\u00fclen CFTR mutasyonlar\u0131n\u0131n olu\u015fumu yeterince ara\u015ft\u0131r\u0131lmam\u0131\u015ft\u0131r. Ayr\u0131ca, n\u00fcfusu a\u011f\u0131rl\u0131kl\u0131 olarak Avrupa d\u0131\u015f\u0131ndaki soylardan gelen \u00fclkelerde KF i\u00e7in de\u011ferlendirme s\u0131n\u0131rl\u0131d\u0131r. Bu t\u00fcr \u00fclkelerde KF i\u00e7in tarama ve de\u011ferlendirmenin daha \u00f6nce g\u00f6zden ka\u00e7m\u0131\u015f KF tan\u0131lar\u0131n\u0131 ortaya \u00e7\u0131karmas\u0131 muhtemeldir. CFTR'de tan\u0131mlanm\u0131\u015f olan yakla\u015f\u0131k 2.000 mutasyonun 500'den az\u0131 tam olarak karakterize edilmi\u015ftir (cftr2.org). Bilinen CFTR mutasyonlar\u0131n\u0131n sonu\u00e7lar\u0131n\u0131 belirlemek i\u00e7in devam eden \u00e7abalar ve <\/span><em><span style=\"font-weight: 400;\">in vitro<\/span><\/em><span style=\"font-weight: 400;\"> Onayl\u0131 tedavilere yan\u0131t\u0131n test edilmesi, herkes i\u00e7in tedaviye uygunlu\u011fu art\u0131racakt\u0131r.\u00a0<\/span><\/p>\n<h5><b>S: KF pop\u00fclasyonunun son 10%'sindeki insanlar i\u00e7in tan\u0131mlay\u0131c\u0131 bakteriyel zorluklar nelerdir ve bunlar di\u011fer 90%'den farkl\u0131 m\u0131d\u0131r?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h5>\n<p><span style=\"font-weight: 400;\">C: KF'li bir\u00e7ok yeti\u015fkinin kronik enfeksiyonlar\u0131 \u00e7oklu ilaca diren\u00e7li (MDR) hale gelmi\u015ftir.  \u00c7oklu ilaca diren\u00e7li bakteriler, CFTR mod\u00fclat\u00f6rlerine uygun olan\/ kullanan KF'li ki\u015filerde oldu\u011fu kadar mod\u00fclat\u00f6r kullanmayanlarda da g\u00f6r\u00fcl\u00fcr. PROMISE \u00e7al\u0131\u015fmas\u0131ndan (*NCT04038047) elde edilen verilere g\u00f6re, elexacaftor-tezacaftor-ivacaftor (Trikafta\u00ae) gibi y\u00fcksek etkili CFTR mod\u00fclat\u00f6rleri mukosiliyer klirensi art\u0131rmaktad\u0131r. PROMISE \u00e7al\u0131\u015fmas\u0131ndan elde edilen ilk veriler, tedavi g\u00f6ren baz\u0131 ki\u015filerde bakterilerin temizlenmesinde art\u0131\u015f oldu\u011funu g\u00f6stermektedir. Eleksakaftor-tezakaftor-ivakaftor (Trikafta\u00ae) kullananlarda erken bakteriyel temizlenmenin zaman i\u00e7inde devam edip etmeyece\u011fi hen\u00fcz bilinmemektedir.\u00a0<\/span><\/p>\n<h5><b>S: KF'li ki\u015filerin kalan 10%'sinin tedavi edilmesinin \u00f6n\u00fcndeki en b\u00fcy\u00fck engeller nelerdir?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h5>\n<p><span style=\"font-weight: 400;\">C: KF y\u00f6netimi tarihinin b\u00fcy\u00fck b\u00f6l\u00fcm\u00fcnde, KF'nin belirti ve semptomlar\u0131n\u0131 tedavi etmeye odakland\u0131k. CFTR mod\u00fclat\u00f6rleri, CFTR mutasyonlar\u0131n\u0131n neden oldu\u011fu baz\u0131 temel kusurlar\u0131 etkileyen ilk tedavilerdir. Bu k\u00fc\u00e7\u00fck molek\u00fcll\u00fc tedaviler protein kusurunu tedavi eder. CFTR mutasyonlar\u0131na ba\u011fl\u0131 olarak mod\u00fclat\u00f6rler i\u00e7in uygun olmayan bir\u00e7ok KF'li ki\u015fi CFTR proteini \u00fcretmez ve bu nedenle temel kusuru ele almak i\u00e7in gen terapisine ihtiya\u00e7 duyabilir. Gen terapisinin \u00f6n\u00fcndeki ba\u015fl\u0131ca engellerden baz\u0131lar\u0131 \u015funlard\u0131r: 1) gen terapisinin hangi hava yolu h\u00fccrelerine verilmesinin en \u00f6nemli oldu\u011funun anla\u015f\u0131lmas\u0131, 2) d\u00fczeltilmi\u015f geni yeterli miktarda veren bir ta\u015f\u0131ma sisteminin geli\u015ftirilmesi ve 3) gen terapisinin g\u00fcvenli olmas\u0131n\u0131n\/a\u015f\u0131r\u0131 bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisine neden olmamas\u0131n\u0131n sa\u011flanmas\u0131.\u00a0\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">*clinicaltrials.gov\u00a0<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Dr. Taylor-Cousar'\u0131n Soru-Cevap b\u00f6l\u00fcm\u00fcnde payla\u015f\u0131lan t\u00fcm bilgiler 5 May\u0131s 2022 tarihi itibariyle do\u011frudur.<\/span><\/i><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">KF ara\u015ft\u0131rmalar\u0131na kat\u0131lmakla ilgileniyor musunuz? Bize kat\u0131l\u0131n <\/span><a href=\"https:\/\/www.emilysentourage.org\/tr\/patient-registry\/\"><span style=\"font-weight: 400;\">KF anlams\u0131z mutasyon hasta kayd\u0131<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>On April 6, 2022, Emily\u2019s Entourage (EE) presented an informational webinar to share the findings of its inaugural global survey on the health and perspectives of people with cystic fibrosis (CF) who do not benefit from currently available mutation-targeted therapies. The results were published in Pediatric Pulmonology. Dr. Jennifer L. Taylor-Cousar, MD, MSCS, ATSF, co-author&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/www.emilysentourage.org\/tr\/webinar-recap-key-findings-from-ees-final-10-survey\/\" class=\"excerpt-read-more\">Daha fazla bilgi edinin<\/a><\/p>","protected":false},"author":1281,"featured_media":16948,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"Webinar Recap: Key Findings From EE\u2019s \u201cFinal 10% Survey\u201d","_seopress_titles_desc":"On April 6, 2022, Emily\u2019s Entourage (EE) presented an informational webinar to share the findings of its inaugural global survey on the health and perspectives of people with cystic fibrosis (CF) who do not benefit from currently available mutation-targeted therapies.","_seopress_robots_index":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-16946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"jetpack_featured_media_url":"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Jennifer-Taylor-Cousar.png","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/16946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/users\/1281"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/comments?post=16946"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/16946\/revisions"}],"predecessor-version":[{"id":16966,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/16946\/revisions\/16966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media\/16948"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media?parent=16946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/categories?post=16946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/tags?post=16946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}